Sugi Predict

Sugi Predict / Compounds / SCHEMBL371886

SCHEMBL371886

SCHEMBL371886

COc1cc2c(Oc3ccc(N(C(=O)C4(C(N)=O)CC4)c4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCN(C)CC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MET P08581 16/20 0.61
▸ AXL P30530 7/20 0.60
▸ EGFR P00533 4/20 0.60
▸ PLK4 O00444 3/20 0.60
▸ AURKA O14965 3/20 0.60
▸ RIPK2 O43353 3/20 0.60
▸ STK10 O94804 3/20 0.60
▸ FYN P06241 3/20 0.60
▸ YES1 P07947 3/20 0.60
▸ LYN P07948 3/20 0.60
▸ SRC P12931 3/20 0.60
▸ FER P16591 3/20 0.60
▸ MAP2K2 P36507 3/20 0.60
▸ CSK P41240 3/20 0.60
▸ ABL2 P42684 3/20 0.60
▸ LIMK1 P53667 3/20 0.60
▸ PTK2 Q05397 3/20 0.60
▸ STK4 Q13043 3/20 0.60
▸ PRKAA1 Q13131 3/20 0.60
▸ TNK1 Q13470 3/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL371898 0.97 MET (0.59) METAXLEGFRPLK4AURKA
SCHEMBL411270 0.95 MET (0.63) METAXLEGFRPLK4AURKA
SCHEMBL372079 0.94 MET (0.58) METAXLEGFRPLK4AURKA
SCHEMBL372099 0.94 MET (0.58) METAXLEGFRPLK4AURKA
SCHEMBL29885881 0.93 MET (0.70) METAXLEGFRPLK4AURKA
SCHEMBL371805 0.93 MET (0.70) METAXLEGFRPLK4AURKA
SCHEMBL372154 0.93 MET (0.59) METAXLEGFRPLK4AURKA
SCHEMBL409723 0.93 MET (0.70) METAXLEGFRPLK4AURKA
Water SCHEMBL2452885 0.93 MET (0.69) METAXLEGFRPLK4AURKA
SCHEMBL371626 0.93 MET (0.63) METAXLEGFRPLK4AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE EXELIXIS, INC. 2021-08-19 — — US claimed
US-20200331860-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2020-10-22 — — US claimed
EP-2101759-B1 METHODS OF USING MEK INHIBITORS EXELIXIS INC (US) 2018-10-10 — — EP claimed
US-20170355678-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2017-12-14 — — US claimed
US-20150376133-A1 C-Met Modulators and Methods of Use EXELIXIS, INC. 2015-12-31 — — US claimed
US-20120184523-A1 C-Met Modulators and Method of Use EXELIXIS, INC. (US) 2012-07-19 — — US claimed
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-09-27 — — US claimed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US claimed
EP-3329918-B1 C-MET MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2022-05-25 — — EP disclosed
US-11124482-B2 C-met modulators and methods of use EXELIXIS, INC. (US) 2021-09-21 — — US disclosed
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE EXELIXIS, INC. 2021-08-19 — — US disclosed
US-20200331860-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2020-10-22 — — US disclosed
EP-2101759-B1 METHODS OF USING MEK INHIBITORS EXELIXIS INC (US) 2018-10-10 — — EP disclosed
EP-3329918-A2 C-MET MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2018-06-06 — — EP disclosed
US-20090170896-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2009-07-02 — — US disclosed
US-20090105299-A1 c-MET MODULATORS AND METHODS OF USE EXELIXIS, INC (US) 2009-04-23 — — US disclosed
US-20080166359-A1 Methods of using MEK inhibitors EXELIXIS, INC. 2008-07-10 — — US disclosed
US-20070244116-A1 c-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-10-18 — — US disclosed
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-09-27 — — US disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200331860-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET MET 3/4885AXL 109/4885EGFR 124/4885
US-20070054928-A1 c-Met modulators and methods of use FLT4, FLT1, MET MET 3/4885AXL 109/4885EGFR 124/4885
US-20150376133-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET MET 3/4885AXL 109/4885EGFR 124/4885
US-20170355678-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET MET 3/4885AXL 109/4885EGFR 124/4885
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE FLT4, FLT1, MET MET 3/4885AXL 109/4885EGFR 124/4885
US-20080166359-A1 Methods of using MEK inhibitors BRAF, NRAS, KRAS MET 312/4885AXL 769/4885EGFR 60/4885
US-20090170896-A1 c-Met modulators and methods of use FLT4, MET, FLT1 MET 2/4885AXL 239/4885EGFR 166/4885
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE FLT4, MET, FLT1 MET 2/4885AXL 241/4885EGFR 181/4885
US-20070244116-A1 c-MET MODULATORS AND METHOD OF USE FLT4, MET, FLT1 MET 2/4885AXL 241/4885EGFR 181/4885
US-11124482-B2 C-met modulators and methods of use FLT4, FLT1, MET MET 3/4885AXL 109/4885EGFR 124/4885
US-20090105299-A1 c-MET MODULATORS AND METHODS OF USE FLT4, MET, FLT1 MET 2/4885AXL 239/4885EGFR 166/4885
US-20120184523-A1 C-Met Modulators and Method of Use FLT4, MET, FLT1 MET 2/4885AXL 241/4885EGFR 181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.